(IPX) IperionX American - Ratings and Ratios
Titanium, Zircon, Rare Earth, Titanium Powder
Dividends
Currently no dividends paid| Risk via 10d forecast | |
|---|---|
| Volatility | 74.6% |
| Value at Risk 5%th | 102% |
| Relative Tail Risk | -17.29% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.55 |
| Alpha | 2.59 |
| CAGR/Max DD | 1.34 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.581 |
| Beta | 1.047 |
| Beta Downside | 1.437 |
| Drawdowns 3y | |
|---|---|
| Max DD | 65.86% |
| Mean DD | 20.28% |
| Median DD | 15.62% |
Description: IPX IperionX American November 17, 2025
IperionX Limited (NASDAQ: IPX) is a U.S.–based miner and metal-powder producer that owns 100 % of the Titan project in Tennessee, a resource package containing titanium, zircon and rare-earth minerals. The firm also manufactures angular and spherical titanium powders for a broad customer base that includes automotive, aerospace, defense, energy, medical, consumer electronics, luxury goods and industrial applications. The company, incorporated in 2017 and headquartered in Charlotte, NC, rebranded from Hyperion Metals in February 2022.
Key quantitative signals (as of the latest filings) include a reported 2023 production capacity of ~30 kt of titanium powder and a 2022 resource estimate of roughly 1.2 Mt of titanium-bearing ore at the Titan project. The titanium market is currently driven by rising demand for lightweight alloys in EVs and aerospace, with the global titanium powder market projected to grow at a CAGR of ~7 % through 2028. A macro-level driver is the U.S. “Domestic Critical Minerals” policy, which offers tax incentives and preferential procurement for domestically sourced critical materials-potentially improving IperionX’s cost structure and market access.
For a deeper, data-rich perspective on how IperionX’s exposure to these trends stacks up against peers, you might find the analytics on ValueRay worth a look.
Piotroski VR‑10 (Strict, 0-10) 0.0
| error: Net Income check cannot be calculated (needs Net Income TTM and Revenue TTM) |
| FCFTA -0.51 (>2.0%) and ΔFCFTA -29.69pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| error: NWC/Revenue cannot be calculated (needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.30 (>3.0%) and CFO -31.8m > Net Income -35.4m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 6.99 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (29.5m) change vs 12m ago 30.47% (target <= -2.0% for YES) |
| error: Gross Margin (current vs previous) cannot be calculated (needs Total Revenue and Cost Of Revenue) |
| Asset Turnover 0.0% (prev 0.0%; Δ 0.0pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -107.1 (EBITDA TTM -37.8m / Interest Expense TTM 366.8k) >= 6 (WARN >= 3) |
Altman Z'' 4.18
| (A) 0.48 = (Total Current Assets 58.9m - Total Current Liabilities 8.43m) / Total Assets 105.0m |
| (B) -1.04 = Retained Earnings (Balance) -109.2m / Total Assets 105.0m |
| warn (B) unusual magnitude: -1.04 — check mapping/units |
| (C) -0.49 = EBIT TTM -39.3m / Avg Total Assets 80.2m |
| (D) 7.34 = Book Value of Equity 92.4m / Total Liabilities 12.6m |
| Total Rating: 4.18 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 34.17
| 1. Piotroski 0.0pt |
| 2. FCF Yield -5.10% |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.04 |
| 5. Debt/Ebitda 1.35 |
| 6. ROIC - WACC (= -39.24)% |
| 7. RoE -35.73% |
| 8. Revenue Trend data missing |
| 9. EPS Trend 59.85% |
What is the price of IPX shares?
Over the past week, the price has changed by -0.95%, over one month by -15.94%, over three months by -28.77% and over the past year by +13.22%.
Is IPX a buy, sell or hold?
- Strong Buy: 2
- Buy: 0
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the IPX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 64 | 91.2% |
| Analysts Target Price | 64 | 91.2% |
| ValueRay Target Price | 45.6 | 36.2% |
IPX Fundamental Data Overview December 03, 2025
P/E Forward = 1250.0
P/B = 11.8509
Beta = 0.799
Revenue TTM = 0.0 USD
EBIT TTM = -39.3m USD
EBITDA TTM = -37.8m USD
Long Term Debt = 3.46m USD (estimated: total debt 3.93m - short term 472.0k)
Short Term Debt = 472.0k USD (from shortTermDebt, last quarter)
Debt = 3.93m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -50.9m USD (from netDebt column, last quarter)
Enterprise Value = 1.04b USD (1.10b + Debt 3.93m - CCE 54.8m)
Interest Coverage Ratio = -107.1 (Ebit TTM -39.3m / Interest Expense TTM 366.8k)
FCF Yield = -5.10% (FCF TTM -53.3m / Enterprise Value 1.04b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 2.63m) / Revenue TTM)
Tobins Q-Ratio = 9.95 (Enterprise Value 1.04b / Total Assets 105.0m)
Interest Expense / Debt = 0.03% (Interest Expense 1323 / Debt 3.93m)
Taxrate = 21.0% (US default 21%)
NOPAT = -31.0m (EBIT -39.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 6.99 (Total Current Assets 58.9m / Total Current Liabilities 8.43m)
Debt / Equity = 0.04 (Debt 3.93m / totalStockholderEquity, last quarter 92.4m)
Debt / EBITDA = 1.35 (negative EBITDA) (Net Debt -50.9m / EBITDA -37.8m)
Debt / FCF = 0.95 (negative FCF - burning cash) (Net Debt -50.9m / FCF TTM -53.3m)
Total Stockholder Equity = 99.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -33.67% (Net Income -35.4m / Total Assets 105.0m)
RoE = -35.73% (Net Income TTM -35.4m / Total Stockholder Equity 99.0m)
RoCE = -38.35% (EBIT -39.3m / Capital Employed (Equity 99.0m + L.T.Debt 3.46m))
RoIC = -29.40% (negative operating profit) (NOPAT -31.0m / Invested Capital 105.6m)
WACC = 9.83% (E(1.10b)/V(1.10b) * Re(9.87%) + D(3.93m)/V(1.10b) * Rd(0.03%) * (1-Tc(0.21)))
Discount Rate = 9.87% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 18.46%
Fair Price DCF = unknown (Cash Flow -53.3m)
EPS Correlation: 59.85 | EPS CAGR: 620.3% | SUE: 0.0 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: 0.0% | SUE: N/A | # QB: 0
EPS current Year (2026-06-30): EPS=-0.07 | Chg30d=-0.025 | Revisions Net=+0 | Growth EPS=+37.5% | Growth Revenue=+0.0%
EPS next Year (2027-06-30): EPS=0.04 | Chg30d=-0.060 | Revisions Net=-2 | Growth EPS=+160.0% | Growth Revenue=+550.1%
Additional Sources for IPX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle